Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.66
- Piotroski Score 2.00
- Grade Buy
- Symbol (EVO)
- Company Evotec SE
- Price $3.52
- Changes Percentage (3.23%)
- Change $0.11
- Day Low $3.46
- Day High $3.55
- Year High $12.40
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 01/11/2019
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $8.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.28
- Trailing P/E Ratio -17.07
- Forward P/E Ratio -17.07
- P/E Growth -17.07
- Net Income $-83,913,000
Income Statement
Quarterly
Annual
Latest News of EVO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
What China's Belt and Road Initiative has in store for coming decade as priorities evolve
China's Belt and Road Initiative is evolving towards smaller, more sustainable projects to address criticisms of debt and environmental impact. The initiative is expanding to Central and Southeast Asi...
By Yahoo! Finance | 15 hours ago -
Ted Cruz attacked by Trevor Reed's dad in new ad
Joey Reed, father of Trevor Reed who was imprisoned in Russia, criticized Ted Cruz for not helping during his son's detention. Reed endorsed Colin Allred, who worked to bring his son home. Trevor Reed...
By Newsweek | 1 day ago -
A tech leader at Accenture shares how AI and cloud tools in the public sector can evolve with regulation: 'It's still the Wild West'
Tom Greiner, a leader at Accenture since 1988, specializes in technology for public services. He discusses cloud technology, data security concerns, AI applications, and regulatory impacts in the publ...
By Business Insider | 1 day ago
